Researchers provide a closer look at a mathematical model and data showing that individual patient alterations in the prostate-specific antigen (PSA) biomarker early in cancer treatment can predict outcomes to later treatment cycles of adaptive therapy.
from Top Health News -- ScienceDaily https://ift.tt/2VmZwXC
Post a Comment